TY - JOUR
T1 - Intracranial hemangiopericytoma - Our experience in 30 years
T2 - A series of 43 cases and review of the literature
AU - Melone, Angelina Graziella
AU - D'Elia, Alessandro
AU - Santoro, Francesca
AU - Salvati, Maurizio
AU - Delfini, Roberto
AU - Cantore, Giampaolo
AU - Santoro, Antonio
PY - 2014
Y1 - 2014
N2 - Objective Meningeal hemangiopericytoma (HPC) is a rare, aggressive central nervous system tumor that tends to invade locally and to metastasize, and has a high rate of recurrence. Methods This study presents a retrospective review of patients managed for intracranial HPC at Rome University Hospital. Results A total of 43 patients with intracranial HPC were treated from 1980 to 2010. Treatment and follow-up information was available for analysis on 36 patients. The median survival for all patients was 83.5 months after date of diagnosis, with 1-year, 5-year, and 10-year survival rates of 100%, 94.4%, and 72.2%, respectively. Eighteen patients (41.86%) had HPC recurrence. The median time until recurrence was 72.24 months, with 1-year, 5-year, and 10-year progression-free survival rates of 98%, 51%, and 29%, respectively. Five patients (11.62%) developed extracranial metastasis. Patients undergoing any form of adjuvant radiation treatment, including external beam radiotherapy, Gamma Knife radiosurgery, and/or proton beam therapy, had no longer median overall survival (OS) (178 vs. 154 months, respectively; P =.2); but did have a significantly improved recurrence-free interval (108 vs. 64 months; P =.04) compared with patients who did not undergo radiation treatment. Tumor characteristics associated with earlier recurrence included size ≥7 cm (log-rank, P
AB - Objective Meningeal hemangiopericytoma (HPC) is a rare, aggressive central nervous system tumor that tends to invade locally and to metastasize, and has a high rate of recurrence. Methods This study presents a retrospective review of patients managed for intracranial HPC at Rome University Hospital. Results A total of 43 patients with intracranial HPC were treated from 1980 to 2010. Treatment and follow-up information was available for analysis on 36 patients. The median survival for all patients was 83.5 months after date of diagnosis, with 1-year, 5-year, and 10-year survival rates of 100%, 94.4%, and 72.2%, respectively. Eighteen patients (41.86%) had HPC recurrence. The median time until recurrence was 72.24 months, with 1-year, 5-year, and 10-year progression-free survival rates of 98%, 51%, and 29%, respectively. Five patients (11.62%) developed extracranial metastasis. Patients undergoing any form of adjuvant radiation treatment, including external beam radiotherapy, Gamma Knife radiosurgery, and/or proton beam therapy, had no longer median overall survival (OS) (178 vs. 154 months, respectively; P =.2); but did have a significantly improved recurrence-free interval (108 vs. 64 months; P =.04) compared with patients who did not undergo radiation treatment. Tumor characteristics associated with earlier recurrence included size ≥7 cm (log-rank, P
KW - Hemangiopericytoma
KW - Intracranial
KW - Recurrence
KW - Survival
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84898029157&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84898029157&partnerID=8YFLogxK
U2 - 10.1016/j.wneu.2013.11.009
DO - 10.1016/j.wneu.2013.11.009
M3 - Article
C2 - 24239740
AN - SCOPUS:84898029157
VL - 81
SP - 556
EP - 562
JO - World Neurosurgery
JF - World Neurosurgery
SN - 1878-8750
IS - 3-4
ER -